主页 / 资源 / 按需随选的网络研讨会 / Part 4: Best Practices for oligonucleotide therapeutic development: Q&A
Part 4: Best Practices for oligonucleotide therapeutic development: Q&A
按需随选的网络研讨会

In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including proteins, oligonucleotides, viral vectors, and engineered cells. One area within Complex Biologics experiencing tremendous growth is oligonucleotide therapies— nucleic acid polymers with the potential to treat or manage a wide range of diseases.

Certara supported the first FDA approval of an oligonucleotide therapy as well as 23 subsequent programs. This video features the Q&A session from our webinar on oligonucleotide therapeutic development.

About Our Speakers

Suzanne Minton

Dr. Suzanne Minton is the Director of Content Strategy at Certara. She holds a BS in biology from Duke University and a PhD in pharmacology from the School of Medicine at the University of North Carolina, Chapel Hill.

Martin Beliveau

Dr. Martin Beliveau has over 10 years of modeling experience in clinical pharmacology. He received a PhD in Public Health from the Université de Montreal under Dr. Kannan Krishnan in physiologically-based pharmacokinetic modeling in 2004.

Virna Schuck

Dr. Virna Schuck is a Senior Director in Clinical Pharmacology and Translational Medicine at Certara. She has a bachelor’s degree in pharmacy and master’s in Pharmaceutical Sciences from the Federal University of Rio Grande do Sul – UFRGS- Brazil, and a PhD in Pharmaceutical Sciences from the College of Pharmacy, University of Florida.

返回顶部
Powered by Translations.com GlobalLink OneLink Software